NEW YORK, April 07, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Biohaven Ltd. (“Biohaven” or the “Company”) (NYSE: BHVN).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Biohaven and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On March 3, 2025 ...

Core Insights - Biohaven Ltd. will present 13 abstracts at the 2025 American Academy of Neurology (AAN) Annual Meeting, showcasing its innovative neuroscience pipeline across various development programs [1][2] Company Developments - The presentations include 3 oral and 10 poster presentations, focusing on potential first-in-class therapies for neurological disorders with high unmet needs [2] - Biohaven's pipeline includes Kv7 ion channel modulation, extracellular protein degradation, TRPM3 antagonism, TYK2/JAK1 inhibition, and glutamate modulation [1][6] Oral Presentations - BHV-8000, a selective TYK2/JAK1 inhibitor, shows efficacy in a Parkinson's disease mouse model [3] - BHV-2100, a first-in-class TRPM3 antagonist, demonstrates safety and tolerability for pain and migraine [3] - Novel bispecific degrader BHV-1310 achieves significant IgG reduction in preclinical models [3] Poster Presentations - A qualitative assessment of the epilepsy patient experience through social media [4] - BHV-2100's development for migraine treatment [5] - A modern design for a Phase 2/3 study evaluating BHV-7000 in idiopathic generalized epilepsy [5] Company Overview - Biohaven focuses on discovering and developing treatments in immunology, neuroscience, and oncology, leveraging its drug development experience and proprietary platforms [6]

Shares of early-stage biotech stocks, including Biohaven (BHVN -8.53%), Recursion Pharmaceuticals (RXRX -6.62%), and CRISPR Therapeutics (CRSP -3.22%), plunged in March, with the stocks down 35.3%, 29.6%, and 22.5%, respectively, according to data from S&P Global Market Intelligence .The stocks endured multiple headwinds during the month, especially Biohaven, which had one of its drug candidates deliver underwhelming results in a recent study. In addition, all money-losing biotechs sold off hard along with ...

NEW YORK, March 4, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Biohaven Ltd ("Biohaven" or the "Company") (NYSE: BHVN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.The investigation concerns whether Biohaven and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On March 3, 2025, Biohaven i ...

Exhibit 99.1 Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2024 Financial Results • Announced acceptance and Priority Review by the United States Food and Drug Administration (FDA) of the new drug application (NDA) for troriluzole in all-genotype spinocerebellar ataxia; expected Prescription Drug User Fee Act (PDUFA) date in 3Q 2025. • Cash, cash equivalents, marketable securities and restricted cash as of December 31, 2024 totaled approximately $489 million. • Reported posi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ____________________________________________________________________________ FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to ______ Commission File Number: 001-41477 Biohaven Ltd. (Exact Name of Registran ...

Core Insights - Biohaven Ltd. has reported significant success with its investigational drug BHV-1300, a potential first-in-class IgG1,2,4 selective degrader, which has shown rapid and deep reductions in total IgG levels, indicating its potential for treating autoimmune diseases [1][3][7] Group 1: BHV-1300 Efficacy and Mechanism - In a four-week Phase 1 study, subcutaneous administration of BHV-1300 at a dose of 1000 mg weekly achieved reductions in total IgG of up to 84%, with a median reduction of 80% [2][3] - The drug selectively targets IgG1,2,4 while sparing IgG3, which is crucial for maintaining immune defense against infections [3][5] - BHV-1300 demonstrated progressive reductions in IgG levels within hours of each dose, with sustained effects over the study period [3][4] Group 2: Safety and Tolerability - BHV-1300 has been reported as safe and well-tolerated, with no clinically significant increases in liver enzymes or bilirubin, and no serious adverse events noted during the study [4][6] - Most adverse events were mild and self-resolving, with no discontinuations due to the study drug [4][6] Group 3: Future Development Plans - Based on the promising results, Biohaven plans to initiate a Phase 2 study in Graves' disease in mid-2025, with additional studies in other autoimmune diseases to follow [3][6] - The company aims to customize treatment approaches based on the depth and speed of IgG lowering achievable with BHV-1300 [3][4] Group 4: Market Context and Unmet Needs - Graves' disease affects approximately 3 million individuals in the US and 80 million globally, highlighting a significant unmet need for effective treatments that do not lead to permanent hypothyroidism or other severe side effects [6][7] - Current treatments for Graves' disease have remained unchanged for 70 years, creating an opportunity for innovative therapies like BHV-1300 to disrupt the existing treatment paradigm [6][7]

Announced acceptance and Priority Review by the United States Food and Drug Administration (FDA) of the new drug application (NDA) for troriluzole in all-genotype spinocerebellar ataxia; expected Prescription Drug User Fee Act (PDUFA) date in 3Q 2025. Cash, cash equivalents, marketable securities and restricted cash as of December 31, 2024 totaled approximately $489 million. Reported positive degrader data with multiple doses of BHV-1300 achieving up to 84% reduction of total IgG, with a median reduction o ...

Group 1 - Biohaven, after its acquisition by Pfizer, has seen a significant increase in valuation, rising from an approximate $7 share price and a $300 million valuation [1] - The new venture led by Vlad Coric has demonstrated a steady growth trajectory in its market valuation [1] Group 2 - No additional relevant content available [2]

Core Insights - The article discusses the Biotech Analysis Central service, which provides in-depth analysis of pharmaceutical companies and investment opportunities in the biotech sector [1][2]. Group 1: Service Offerings - Biotech Analysis Central offers a library of over 600 biotech investing articles, a model portfolio of more than 10 small and mid-cap stocks, and live chat features for investors [2]. - The service is available for $49 per month, with a discounted annual plan at $399, representing a 33.50% savings [1]. Group 2: Analyst Background - The author of the article runs the Biotech Analysis Central service and emphasizes the depth of analysis provided for healthcare investors [2]. - The article does not indicate any personal investment positions in the companies discussed, ensuring an unbiased perspective [3].